Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

Elie El Rassy 1Marwan Ghosn 1Fadi Farhat 1 2Ziad Bakouny 1Tarek Assi 1Georges Chahine 1 3Fadi Nasr 1 4Fady Ghassan Haddad 1Fadi El Karak 1Joseph Kattan 1 5


1Department of Hematology-Oncology, Hotel-Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

2Department of Medical Oncology, Hammoud Hospital, Saida, Lebanon.

3Department of Medical Oncology, Notre Dame de Secours Hospital, Byblos, Lebanon.

4Department of Medical Oncology, Mount Lebanon Hospital, Hadath, Lebanon.

5Department of Medical Oncology, Saint Joseph Hospital, Baouchrieh, Lebanon.

PMID: 29887789

PMCID: PMC5981632

DOI: 10.1159/000481339

Free PMC article


Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer.

Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012.

Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common.

Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

Keywords: Adverse events; Breast cancer; Docetaxel; Safety; Toxicity.